To confirm the involvement of CXCR2 in neutrophil-tumor interactions, further experiments can be performed to inhibit the CXCR2 pathway using other methods than pharmacological antagonism (AZD-5069), such as knockout of CXCR2 in HL-60 cells. This evidence concerns the gene CXCR2 and neoplasm.